AR049580A1 - CARBAMILATED EPO AND METHOD FOR YOUR PRODUCTION - Google Patents
CARBAMILATED EPO AND METHOD FOR YOUR PRODUCTIONInfo
- Publication number
- AR049580A1 AR049580A1 ARP050102809A ARP050102809A AR049580A1 AR 049580 A1 AR049580 A1 AR 049580A1 AR P050102809 A ARP050102809 A AR P050102809A AR P050102809 A ARP050102809 A AR P050102809A AR 049580 A1 AR049580 A1 AR 049580A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- less
- erythropoietin
- carbamylated
- amount
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Un método para la produccion de una proteína de eritropoyetina carbamilada que tiene menos de aproximadamente 40% de proteína agregada y menos de aproximadamente 40% en peso de proteína sobre- y subcarbamilada, medida por espectrometría de masa ESI, donde dicho método comprende poner en contacto una cantidad de eritropoyetina con una cantidad de cianato, a una temperatura, un pH y durante un tiempo suficientes para que los grupos amina en las lisinas y los aminoácidos N-terminales de la eritropoyetina se carbamilen en al menos aproximadamente de 90%. Reivindicacion 23: Un método para la produccion de una proteína de eritropoyetina carbamilada que tiene menos de aproximadamente 3% de proteína agregada y menos de aproximadamente 40% en peso de proteína sobre- y subcarbamilada, medida por espectrometría de masa ESI, donde dicho método comprende: (a) el contacto de una cantidad de una proteína de eritropoyetina con una cantidad de cianato, a una temperatura, un pH y durante un tiempo suficientes para que al menos aproximadamente el 90% de los residuos amina en la lisina y los aminoácidos N-terminales de la eritropoyetina se carbamilen; y (b) la purificacion de la proteína de eritropoyetina carbamilada usando intercambio anionico, intercambio cationico, cromatografía de interaccion hidrofoba, cromatografía de fase inversa, cromatografía de afinidad o cromatografía de exclusion por tamano. Reivindicacion 44: Una proteína de eritropoyetina carbamilada que tiene al menos aproximadamente 90% de carbamilacion de las aminas primarias de la lisina y los aminoácidos amino terminales; menos de aproximadamente 3% de proteína agregada; y menos de aproximadamente 40% en peso de proteína sobre- y subcarbamilada, medida por espectrometría de masa ESI. Reivindicacion 61: Una composicion farmacéutica que comprende una cantidad terapéuticamente eficaz de una proteína de eritropoyetina carbamilada que tiene al menos aproximadamente 90% de carbamilacion de las aminas primarias de la lisina y los aminoácidos amino terminales; menos de aproximadamente 3% de proteína agregada; y menos de aproximadamente 40% en peso de proteína sobre- y subcarbam,ilada, y un portador farmacéuticamente aceptable. Reivindicacion 76: El uso de acuerdo con la reivindicacion 75, donde la enfermedad es un accidente cerebrovascular, un evento isquémico, una lesion de la médula espinal, una lesion cerebral traumática, esclerosis multiple, esclerosis lateral amiotrofica, enfermedad de Alzheimer, esquizofrenia o neuropatía inducida por quimioterapia.Claim 1: A method for the production of a carbamylated erythropoietin protein having less than about 40% added protein and less than about 40% by weight of over- and subcarbaminated protein, measured by ESI mass spectrometry, wherein said method comprises contacting an amount of erythropoietin with an amount of cyanate, at a temperature, a pH and for a time sufficient for the amine groups in the lysines and the N-terminal amino acids of erythropoietin to be carbamylated at least about 90% . Claim 23: A method for the production of a carbamylated erythropoietin protein having less than about 3% added protein and less than about 40% by weight of over- and subcarbaminated protein, measured by ESI mass spectrometry, wherein said method comprises : (a) the contact of an amount of an erythropoietin protein with an amount of cyanate, at a temperature, a pH and for a time sufficient for at least about 90% of the amine residues in lysine and amino acids N -eterminals of erythropoietin are carbamilen; and (b) purification of the carbamylated erythropoietin protein using anion exchange, cation exchange, hydrophobic interaction chromatography, reverse phase chromatography, affinity chromatography or size exclusion chromatography. Claim 44: A carbamylated erythropoietin protein having at least about 90% carbamylation of primary lysine amines and amino terminal amino acids; less than about 3% protein added; and less than about 40% by weight of over- and subcarbaminated protein, measured by ESI mass spectrometry. Claim 61: A pharmaceutical composition comprising a therapeutically effective amount of a carbamylated erythropoietin protein having at least about 90% carbamylation of primary lysine amines and amino terminal amino acids; less than about 3% protein added; and less than about 40% by weight of protein over- and subcarbam, ilated, and a pharmaceutically acceptable carrier. Claim 76: The use according to claim 75, wherein the disease is a stroke, an ischemic event, a spinal cord injury, a traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, schizophrenia or neuropathy Chemotherapy-induced
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200401075 | 2004-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049580A1 true AR049580A1 (en) | 2006-08-16 |
Family
ID=36940544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102809A AR049580A1 (en) | 2004-07-07 | 2005-07-06 | CARBAMILATED EPO AND METHOD FOR YOUR PRODUCTION |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN1997665B (en) |
| AR (1) | AR049580A1 (en) |
| MY (1) | MY144200A (en) |
| TW (1) | TWI355275B (en) |
| ZA (1) | ZA200700091B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105233256A (en) * | 2015-10-28 | 2016-01-13 | 中国人民解放军第三军医大学 | Application of erythropoietin and erythropoietin derivatives to preparation of medicine for promoting apoptotic cell clearance during disease treatment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1525889A1 (en) * | 2000-05-15 | 2005-04-27 | F. Hoffmann-La Roche Ag | Liquid pharmaceutical composition containing an erythropoietin derivative |
-
2005
- 2005-07-06 AR ARP050102809A patent/AR049580A1/en not_active Application Discontinuation
- 2005-07-07 CN CN2005800227404A patent/CN1997665B/en not_active Expired - Fee Related
- 2005-07-07 ZA ZA200700091A patent/ZA200700091B/en unknown
- 2005-07-07 MY MYPI20053104A patent/MY144200A/en unknown
- 2005-07-07 TW TW094122948A patent/TWI355275B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TWI355275B (en) | 2012-01-01 |
| CN1997665B (en) | 2011-06-08 |
| TW200612979A (en) | 2006-05-01 |
| ZA200700091B (en) | 2008-09-25 |
| MY144200A (en) | 2011-08-15 |
| CN1997665A (en) | 2007-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bernier et al. | Purification and characterization of a basic 23 kDa cytosolic protein from bovine brain | |
| Aggarwal et al. | Human tumor necrosis factor. Production, purification, and characterization. | |
| PT96068A (en) | PROCESS FOR THE PRODUCTION OF BIOLOGICALLY ACTIVE PROTEINS | |
| ES2188665T3 (en) | PROCEDURE FOR THE PREPARATION OF CARDIODYLATIN FRAGMENTS, VERY PURIFIED CARDIODYLATIN FRAGMENTS AND INTERMEDIATE PRODUCTS FOR PREPARATION. | |
| HRP20040712B1 (en) | Anti-amyloid beta antibodies and their use | |
| DE69535074D1 (en) | PEPTIDE FRAGMENT OF THE G-PROTEIN OF RESPIRATORY SYNCYTIALVIRUS, IMMUNOGENIC COMPOUND AND PHARMACEUTICAL COMPOSITION THAT CONTAIN IT, AND METHOD OF MANUFACTURE | |
| EA200300942A1 (en) | DERIVATIVES N- (ARYLSULPHONYL) BETA AMINO ACIDS CONTAINING A SUBSTITUTE AMINOMETHYL GROUP, METHOD OF THEIR PRODUCTION AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
| Benuck et al. | Metabolic instability of myelin proteins: Breakdown of basic protein induced by brain cathepsin D | |
| OA06421A (en) | Process for the preparation of N- (vinblastinoyl-23) derivatives of amino acids and peptides. | |
| PT94732A (en) | A process for the preparation of compositions comprising a polypeptide of the morphogenetic protein of OSSEO | |
| BR0112538A (en) | Stable salts of o-acetylsalicylic acid with basic amino acids | |
| RS51512B (en) | Process for the purification of interferon proteins through cationic exchange chromatography | |
| BR0114475A (en) | Cell for the production of antibody composition | |
| IT1196500B (en) | MALONIC ACID DERIVATIVES AND METHODS FOR THEIR SYNTHESIS | |
| ES2270152T3 (en) | POSITIONAL ISOMERS OF THE INTERFERON ALFA 2A PEGILADO. | |
| ES2181668T3 (en) | TRI- AND TETRA-SUBSTITUTED GUANIDINS AND ITS USE AS EXCITING AMINO ACID ANTAGONISTS. | |
| DE69024230D1 (en) | AMINO ACIDS, PEPTIDES OR DERIVATIVES BONDED TO FATS | |
| RU2017127012A (en) | IL-17A-linked polypeptides | |
| AR035077A1 (en) | VARIOUS NEUBLASTIN POLYPEPTIDES, FUSION PROTEINS, NUCLEIC ACIDS, VECTORS, HOSPED CELLS, METHODS TO PRODUCE SUCH POLYPEPTIDES, DIMERES, CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND USE OF THESE MEDICINES | |
| IL206157A (en) | Type 1 pancreatic elastase protein, a nucleic acid molecule encoding the protein, a vector, a host cell, methods of producing the protein and a pharmaceutical composition comprising the protein and the use thereof | |
| Joris et al. | The Complete Amino Acid Sequence of the Zn2+‐Containing d‐Alanyl‐d‐Alanine‐Cleaving Carboxypeptidase of Streptomyces albus G | |
| ATE81510T1 (en) | METHODS OF SOLUBILITY, PURIFICATION AND CHARACTERIZATION OF PROTEINS FROM INSOLUBLE PROTEIN AGGREGATES OR PROTEIN COMPLEXES AND RELATED PREPARATIONS. | |
| AR049580A1 (en) | CARBAMILATED EPO AND METHOD FOR YOUR PRODUCTION | |
| PT81528B (en) | PROCESS FOR THE SYNTHESIS OF PEPTIDEES | |
| Nellis et al. | Characterization of recombinant human IL-15 deamidation and its practical elimination through substitution of asparagine 77 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |